Anus Laboratories
In the Dec 2025 quarter, revenue was ₹459 Cr, against ₹167 Cr a year earlier and net profit was ₹109 Cr, against −₹22 Cr a year earlier (compared with Dec 2024). Promoters held 52.41% of Anus Laboratories in Dec 2025, down 0.01 percentage points from Sep 2025.
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| ₹1,766.10 | 35.03 | 4,23,747 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,626.00 | 87.37 | 2,55,540 Cr | 15.25 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,596.10 | 72.15 | 1,74,821 Cr | 9.51 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,183.80 | 107.90 | 1,17,993 Cr | 22.26 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,180.50 | 26.27 | 1,17,755 Cr | 4.34 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,340.80 | 34.73 | 1,11,914 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,370.90 | 32.84 | 1,10,749 Cr | 3.13 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
Anus Laboratories (this company) | — | — | — | — | — | — | — | 53 Cr | 293 Cr |
| Median 8 companies | ₹1,766.10 | 35.03 | 1,17,993 Cr | 5.07 | 0.61% | 13.79% | 17.94% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100. How it works →
No Tapetide Score has been computed for this stock yet.
Key Insights
Strengths
1- Stock is trading at 0.04 times its book value
Weaknesses
5- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 8.50% over last 3 years.
- Dividend payout has been low at 3.80% of profits over last 3 years
- Company's cost of borrowing seems high
Growth Rate
change over 1 year
change over 1 year
Quarterly Results
| Particulars | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 187 | 255 | 98 | 18 | 82 | 14 | 188 | 8 | 167 | 9 | 32 | 18 | 459 |
| Expenses | 198 | 283 | 141 | 53 | 121 | 68 | 230 | 55 | 193 | 64 | 87 | 70 | 429 |
| Operating Profit | -11 | -27 | -43 | -35 | -39 | -54 | -42 | -48 | -25 | -55 | -55 | -52 | 30 |
| OPM % | -6% | -11% | -44% | -196% | -48% | -379% | -22% | -627% | -15% | -597% | -172% | -299% | 6% |
| Other Income | 51 | 38 | 37 | 8 | 82 | 119 | 55 | 45 | 28 | 149 | 107 | 112 | 107 |
| Interest | 3 | 3 | 4 | 0 | 0 | 3 | 6 | 7 | 4 | 2 | 4 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 6 | 6 | 7 | 6 |
| PBT | 33 | 4 | -14 | -30 | 39 | 59 | 3 | -14 | -5 | 87 | 42 | 51 | 129 |
| Tax % | -4% | 86% | -69% | -36% | -28% | -22% | -314% | 0% | 336% | 2% | -23% | 6% | 16% |
| Net Profit | 34 | 1 | -4 | -19 | 50 | 71 | 13 | -14 | -22 | 85 | 51 | 48 | 109 |
| EPS (₹) | 1.56 | 0.02 | -0.2 | -0.89 | 2.35 | 3.36 | 0.6 | -0.66 | -1.05 | 3.99 | 2.4 | 2.25 | 5.1 |
Profit & Loss
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
|---|---|---|---|---|---|---|---|
| Sales | 83 | 104 | 146 | 155 | 198 | 262 | 256 |
| Expenses | 72 | 81 | 111 | 120 | 161 | 216 | 217 |
| Operating Profit | 11 | 23 | 35 | 35 | 36 | 46 | 40 |
| OPM % | 13% | 22% | 24% | 23% | 18% | 18% | 15% |
| Other Income | 1 | 1 | 3 | 0 | 2 | -4 | 0 |
| Interest | 3 | 5 | 8 | 7 | 11 | 17 | 26 |
| Depreciation | 1 | 1 | 1 | 2 | 2 | 4 | 8 |
| PBT | 8 | 18 | 28 | 26 | 26 | 21 | 6 |
| Tax % | 26% | 26% | 36% | 37% | 19% | 37% | 46% |
| Net Profit | 6 | 14 | 18 | 16 | 21 | 13 | 3 |
| EPS (₹) | — | — | — | 0.67 | — | — | 0.14 |
| Div. Payout % | 14% | 6% | 7% | 12% | 11% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 8 | 8 | 12 | 24 | 24 | 24 |
| Reserves | 7 | 24 | 43 | 134 | 137 | 138 | 141 |
| Borrowings | 18 | 27 | 41 | 41 | 81 | 97 | 131 |
| Other Liabilities | 17 | 22 | 34 | 38 | 40 | 33 | 38 |
| Total Liabilities | 48 | 81 | 126 | 224 | 282 | 292 | 334 |
| Fixed Assets | 14 | 21 | 22 | 27 | 43 | 94 | 94 |
| CWIP | 0 | 4 | 4 | 17 | 38 | 22 | 35 |
| Investments | 2 | 3 | 3 | 3 | 3 | 0 | 0 |
| Other Assets | 32 | 53 | 97 | 178 | 198 | 176 | 205 |
| Total Assets | 48 | 81 | 126 | 224 | 282 | 292 | 334 |
Cash Flow
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
|---|---|---|---|---|---|---|---|
| Operating | -5 | 3 | -7 | -42 | 13 | 28 | -10 |
| Investing | -6 | -13 | -3 | -19 | -40 | -23 | -19 |
| Financing | 10 | 11 | 9 | 63 | 27 | -4 | 26 |
| Net Cash Flow | 0 | 2 | -1 | 2 | 1 | 2 | -3 |
| Free Cash Flow | -9 | -9 | -10 | -61 | -26 | 6 | -29 |
| CFO/OP | -43 | 14 | -19 | -83 | 60 | 74 | -18 |
Ratios
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 22 | 26 | 57 | 146 | 124 | 77 | 119 |
| Inventory Days | 165 | 212 | 231 | 269 | 206 | 140 | 135 |
| Days Payable | 91 | 92 | 63 | 85 | 72 | 13 | 12 |
| Cash Conversion Cycle | 96 | 145 | 225 | 330 | 258 | 204 | 242 |
| Working Capital Days | 72 | 112 | 163 | 317 | 281 | 169 | 206 |
| ROCE % | — | 52% | 48% | 25% | 17% | 17% | 12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Anus Laboratories insights
64 extracted metrics + investor summaries across FY06–FY26.
Documents
Frequently Asked Questions about Anus Laboratories
What does Anus Laboratories Ltd do?
Where is Anus Laboratories Ltd (532981) listed?
Which sector does Anus Laboratories Ltd belong to?
Company Information
Anu's Laboratories Limited manufactures and supplies drug intermediates and related products for the pharmaceutical industry.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/532981.md for Anus Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.